Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
Strategic Plan
Whats New at the pCPA
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Nerlynx (neratinib)
pCPA File Number:
21178
Negotiation Status:
Negotiations were not pursued
Indication(s):
Hormone Receptor-Positive Breast Cancer
Sponsor/Manufacturer:
Knight Therapeutics
CADTH Project Number:
10172
pCPA Engagement Letter Issued:
2020-02-04
Negotiation Process Concluded:
2020-02-04